LLS Creates Research Partnership With Celgene
The Leukemia & Lymphoma Society (LLS) and the biopharmaceutical Celgene Corporation have announced a partnership that aims to identify and fund promising blood cancer research projects.
The partnership is the first for LLS's new "Targets, Leads & Candidates Program," a novel approach to venture philanthropy partnerships with the pharmaceutical industry.
The LLS regards such partnerships as crucial for patients since they can potentially bring together innovation from academia and the resources of the pharmaceutical industry in order to expedite novel, life-saving therapies.
"LLS is pleased to be collaborating with Celgene, a company known for innovation in research, to advance both basic academic research in the hematological malignancies, as well as the clinical-development stage projects in our TAP pipeline," said LLS Chief Mission Officer Louis J. DeGennaro, Ph.D. "As always, our goal is getting new therapies to patients more quickly."
"Celgene shares with LLS a deep commitment to high impact treatment for patients with leukemia and lymphoma," said Thomas Daniel, M.D., Celgene President, Research and Early Development. "Through this relationship, we look forward to working with LLS to accelerate delivery of promising therapies to patients."
Source: LLS
More Articles
More Articles
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
Site Beginnings
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...
